echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The original research meets the strong enemy!

    The original research meets the strong enemy!

    • Last Update: 2022-05-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Voriconazole is a second-generation triazole antifungal with broad-spectrum antifungal activity and is the first-line treatment for invasive Aspergillus and Candida krusei infections
    .
    In China's public medical institutions' terminal systemic antifungal drug oral market, voriconazole's sales topped the list, with sales exceeding 4 billion yuan in 2020
    .
    Among them, voriconazole for injection is the main product, accounting for half of the country
    .
    The original research company of voriconazole is Pfizer, but due to the impact of generic drugs, its market share has been declining year by year in recent years
    .
    In the fourth batch of national centralized drug procurement in 2021, two domestic pharmaceutical companies including Huahai Pharmaceutical won the bid for voriconazole products.
    Through "exchanging price for quantity", they will gain more market share, and will also generate more market share for the original research companies.
    big impact
    .
    Judging from the newly classified production of voriconazole for injection and the situation under review, at least 12 companies are involved, including Huahai Pharmaceutical, Livzon Group, Yangzijiang, Qilu Pharmaceutical, and Borui Pharmaceutical
    .
    In terms of consistency evaluation, recently, the State Food and Drug Administration released information showing that Hainan Bite Pharmaceutical's voriconazole for injection was approved for marketing, and it is regarded as a drug that has passed the consistency evaluation of the quality and efficacy of generic drugs, which also shows its quality and efficacy.
    Like the original drug, it can better meet the clinical medication needs of patients
    .
    This product has also become the first domestically reviewed product
    .
    In addition to Beite Pharmaceuticals, Sichuan Meida Kanghuakang Pharmaceuticals also submitted a supplementary application for the consistency evaluation of voriconazole for injection, but it is still under review and approval
    .
    According to relevant national policies, drug varieties that have passed the consistency evaluation will receive greater support in the fields of medical insurance payment and procurement by medical institutions
    .
    This time, Better Pharmaceuticals has won the first review, and its competitiveness has been improved.
    It will compete with the original researcher for a large variety of antifungal drugs of over 2 billion yuan
    .
    The industry pointed out that consistency evaluation is also related to whether pharmaceutical companies can participate in the national centralized drug procurement, and to a certain extent has become the market "ticket" for pharmaceutical companies
    .
    With the normalization of centralized procurement, pharmaceutical companies are accelerating the process of generic drug consistency evaluation in order to obtain the qualifications to participate in centralized procurement and gain more market share
    .
    Hainan Better Pharmaceutical is a holding subsidiary of Better Pharmaceuticals.
    In recent years, it is actively promoting the consistency evaluation of generic drugs
    .
    In addition to voriconazole for injection, the company has also submitted applications for generic marketing of products such as gadoteric acid meglumine injection, gadobe meglumine injection, sodium valproate concentrated solution for injection, posaconazole injection, etc.
    Supplementary application for the evaluation of generic drug consistency with ozagrel sodium
    .
    According to the prospectus, Better Pharmaceuticals regards product quality as the foundation of its enterprise.
    The company has rich experience in production management, and its management team has formulated quality management rules and regulations covering all key aspects of production
    .
    Since the beginning of this year, the company has made many achievements in the consistency evaluation of generic drugs.
    In addition to the over-evaluation of voriconazole for injection by the holding subsidiary Hainan Better Pharmaceuticals, which has become the first domestic company, not long ago, the company's salbutamol sulfate injection was also approved for listing.
    Review the head of the breed
    .
    The data shows that in-hospital sales of salbutamol sulfate injection have exceeded 400 million yuan in recent years, and will fall to 290 million in 2020, and may return to the previous level in 2021
    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.